Interstitial Cystitis
Also known as: Bladder pain syndrome, IC, PBS, Painful bladder syndrome
Methodology & AI Transparency ⓘ
Interstitial Cystitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Interstitial cystitis (IC) is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently.
- 2 Real-world patient consensus: Diagnostic registry R39.82: Interstitial Cystitis is managed within Urology & Prostate (aka Bladder pain syndrome).
- 3 Typical cash cost range: Primary evaluation for Interstitial Cystitis incorporates IPSS symptom scoring [Interstitial Cystitis R39.82] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Interstitial Cystitis monitoring tracks Urinalysis & Post-Void in Interstitial Cystitis (R39.82: Residual (PVR)) toward Negative leukocyte/nitrite; PVR < 50 mL (R39.82).
Ask our AI Specialists anything about Interstitial Cystitis
What Is Interstitial Cystitis?
Interstitial cystitis (IC) is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. It is far more common in women than in men. The symptoms vary from person to person. Some people may have pain without urgency or frequency. Others have urgency and frequency without pain. Women's symptoms often get worse during their periods. They may also have pain with sexual intercourse. The cause of IC isn't known. There is no one test to tell if you have it. Doctors often run tests to rule out other possible causes of symptoms. There is no cure for IC, but treatments can help most people feel better.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Interstitial Cystitis (R39.82) center on uropathogenic bacterial mucosal in Interstitial Cystitis (R39.82: adherence (cystitis) or). Cross-referenced with NIH MeSH (Cystitis, Interstitial), targeted urology & prostate interventions aim to normalize Urinalysis & Post-Void in Interstitial Cystitis (R39.82: Residual (PVR)).
Common Symptoms & Clinical Signs
- • Distending, or inflating, the bladder
- • Bathing the inside of the bladder with a drug solution
- • Presentation of Interstitial Cystitis (R39.82): waking two or in Interstitial Cystitis (R39.82: more times nightly)
- • Secondary Interstitial Cystitis clinical sign: burning dysuria, suprapubic in Interstitial Cystitis (R39.82: discomfort, or cloudy/hematuric)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Interstitial Cystitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R39.82 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Interstitial Cystitis (R39.82: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (R39.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Interstitial Cystitis (R39.82: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (R39.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Interstitial Cystitis (R39.82: Score) | 0 – 7 (mild symptoms) (R39.82) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Interstitial Cystitis
Treatment selection for Interstitial Cystitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Interstitial Cystitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Long-Term safety and real-world benefits of Tocilizumab in Early Systemic Long-term safety was consistent with the known safety profile of tocilizumab. American journal of respiratory and critical care medicine • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34851799 ↗ |
| Can This Approach Help? Inside the Latest Research on Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on These analyses of data from the SENSCIS trial suggest that patients with SSc-ILD who are ACA positive or ARA positive can experience progression of SSc-ILD. The Journal of rheumatology • 2025-09-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40233987 ↗ |
| Can This Approach Help? Inside the Latest Research on Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Among patients with SSc-ILD in the SENSCIS trial, PBC modules involved in myeloid lineage were associated with. Arthritis & rheumatology (Hoboken, N.J.) • 2025-12-15 • Phase III Randomized Trial | N = 120 | 88/100 | PMID 40420438 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of tocilizumab in Japanese patients with systemic sclerosis The real-world benefits and safety of tocilizumab in patients with systemic sclerosis were consistent between the Japanese subpopulation and the global trial population. Modern rheumatology • 2024-03-28 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37436828 ↗ |
| Can This Approach Help? Inside the Latest Research on A composite endpoint for systemic sclerosis-associated interstitial lung disease: The results of this post-hoc analysis provide further evidence that a composite endpoint comprised of physiological, radiological and patient-reported outcomes is a promising endpoint for SSc-ILD trials. Respiratory research • 2025-11-28 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41316297 ↗ |
Interstitial Cystitis Patient Community & “People Like Me” Threads
Filter Interstitial Cystitis community threads and patient logs by age, biological sex, dosage, and treatment duration.